pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104

Table 2 Selected patient characteristics and molecular marker results in the translational study population (n = 153)

Parameter	p-ERK (n = 153)		p-AKT (n = 35)		p53 (n = 50)
Parameter	pERK ^low	pERK ^high	pAKT ^low	pAKT ^high	Loss	Regular	Overexpression
	n = 55	n = 98	n = 21	n = 14	n = 4	n = 20	n = 26
	n	n	n	n	n	n	n
Age [years]
Median	66	63 p = 0.45	64	61 p = 0.27	61	61	65 p = 0.50
Gender
Male	32	58 p = 1.00	12	7 p = 0.74	1	10	15 p = 0.48
Female	23	40	9	7	3	10	11
Stage of disease
Locally advanced	7	19 p = 0.37	1	1 p = 1.00	2	1	3 p = 0.08
Metastatic	48	79	20	13	2	19	23
Performance status
KPS 60-80%	23	36 p = 0.73	8	3 p = 0.46	0	4	12 p = 0.07
KPS 90-100%	31	57	13	11	4	16	14
CA 19–9 [U/ml]
Median	1118	2030 p = 0.19	1975	3154 p = 0.74	1894	3084	1539 p = 0.95
Treatment arm
Gem + E	27	58 p = 0.24	9	10 p = 0.17	2	12	14 p = 0.91
Cap + E	28	40	12	4	2	8	12

Abbreviations: Cap Capecitabine, E Erlotinib, Gem Gemcitabine, KPS Karnofsky performance status.

ISSN: 1471-2407